EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms

Nastaran Kordjazy, Shahideh Amini

Therapeutic Advances in Respiratory Disease · 2024-01 · 18

DOI: 10.1177/17534666241232284 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 19.03.2024. Verfasst von Nastaran Kordjazy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Bronchiolitis Obliterans, Bronchiolitis Obliterans Syndrome, Lung Transplantation, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung and hematopoietic stem cell transplantation are therapeutic modalities in chronic pulmonary and hematological diseases, respectively. One of the complications in these patients is the development of bronchiolitis obliterans syndrome (BOS). The efficacy and safety of available treatment strategies in BOS remain a challenge. A few mechanisms have been recognized for BOS in lung transplant and graft- versus-host disease (GVHD) patients involving the TH-1 and TH-2 cells, NF-kappa B, TGF-b, several cytokines and chemokines, and cysteinyl leukotrienes (CysLT). Montelukast is a highly selective CysLT receptor antagonist that has been demonstrated to exert anti-inflammatory and anti-fibrotic effects in abundant experiments. One area of interest for the use of montelukast is lung transplants or GVHD-associated BOS. Herein, we briefly review data regarding the mechanisms involved in BOS development and montelukast administration as a treatment modality for BOS, and finally, the possible relationship between CysLTs antagonism and BOS improvement will be discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchiolitis ObliteransBronchiolitis Obliterans SyndromeLung TransplantationHematopoietic Stem Cell TransplantationGraft vs Host DiseaseAcetatesCyclopropanesQuinolinesSulfidesHumansLeukotriene AntagonistsLungLeukotrienes

Stichwörter der Autor:innen

GVHDHSCTbronchiolitis obliterans syndromecysteinyl leukotrieneslung transplantmontelukast

Substanzen

Leukotriene AntagonistsmontelukastLeukotrienesAcetatesCyclopropanesQuinolinesSulfides

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Rajaei Cardiovascular Medical and Research Institute, Valiasr Ave-Niyayesh Intersection, Tehran 199561-14331, Iran.

Zitieren

APA

Kordjazy, N., & Amini, S. (2024). A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms. Therapeutic Advances in Respiratory Disease, 18. https://doi.org/10.1177/17534666241232284

Vancouver

Kordjazy N, Amini S. A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms. Therapeutic Advances in Respiratory Disease. 2024;18. doi:10.1177/17534666241232284

BibTeX
@article{Kordjazy2024,
  author = {Kordjazy, Nastaran and Amini, Shahideh},
  title = {A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2024},
  volume = {18},
  doi = {10.1177/17534666241232284}
}
Kostenlos starten →